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Abstract
Introduction: A growing interest has arisen in salivary proteomics as a tool for the identification of biomarkers for
primary Sjögren’s syndrome (pSS). Nonetheless, only a limited number of preclinical validation studies have been
performed, limiting the possibility of translating proteomic results into clinical practice. The primary aim of this
study was to refine the diagnostic power of a panel of candidate salivary biomarkers described in pSS with respect
to both healthy volunteers and pathological controls. We also explored the pathogenetic function of the detected
putative biomarkers both in the local exocrinopathy and in the systemic inflammatory processes of SS.
Methods: One hundred and eighty patients were included in the study overall. In the first “exploratory phase”, we
enrolled 40 females with pSS, 40 sex- and age-matched healthy volunteers, 10 patients with sicca non-SS and 15
secondary SS (sSS) patients. The testing cohort of the second “challenge phase” of the study was represented by
75 unselected, consecutive subjects: 19 pSS, 21 healthy volunteers, 10 sicca non-SS and 25 sSS patients. Salivary
proteomic analysis was performed combining two-dimensional electrophoresis (2DE) and matrix-assisted laser
desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF-MS). Western blot (WB) analysis and enzyme-
linked immunosorbent assay (ELISA) were employed to validate 2DE results. Ingenuity Pathway Analysis (IPA)
Knowledge base was adopted to associate candidate biomarkers in a signalling pathogenetic network.
Results: A total of 28, 6, 7 and 12 protein spots were found to be significantly different in pSS samples with
respect to healthy volunteers, non-SS sicca syndrome, SSc-sSS and rheumatoid arthritis-sSS, leading to the
identification of 15 differently expressed proteins. Among them, a-amylases precursor, carbonic anhydrase VI, b-2
microglobulin, glyceraldehydes-3-phosphate dehydrogenase (G3PDH), epidermal fatty acid binding protein (E-FABP)
and immunoglobulin k light chain (IGK-light chain) apparently showed the most significant differences in pSS
when compared to healthy volunteers and non-SS pathological controls. On the other hand, as expected, pSS and
sSS salivary profiles shared a great number of similarities.
Conclusions: This study demonstrated that salivary fluid might represent a novel ideal milieu for the detection of
a diagnostic panel of candidate biomarkers for pSS, and to gain an insight into the pathogenetic processes
underlying glandular and systemic autoimmune disorders.
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Introduction
Sjögren’s syndrome (SS) is an autoimmune exocrinopa-
thy characterised by the infiltration of salivary and lacri-
mal glands by mononuclear cells with secondary
destruction of the parenchymal tissue, resulting in oral
and ocular dryness [1,2]. Several glandular and extra-
glandular manifestations may be part of the full spec-
trum of the disease, which might severely affect the
patients’ prognosis and quality of life [3-7]. The com-
plexity of SS clinical presentation is increased by the
fact that SS may occur alone, as a primary condition
(primary Sjögren’s syndrome-pSS), or in association with
other connective tissue diseases, including rheumatoid
arthritis (RA) and systemic sclerosis (SSc) as secondary
SS (sSS) [8-10].
In order to improve the diagnostic algorithm for pSS,
during the last few years, growing interest has been
raised for salivary proteomics as a promising tool for
the discovery of disease biomarkers both for pSS and for
other autoimmune and non-autoimmune disorders
[11-17]. In particular, saliva, which may closely reflect
the underlying pathogenetic process in salivary glands,
has been viewed as an attractive biofluid for proteomic
research in pSS and a number of studies have so far
outlined the potential differences between pSS and
healthy controls [11-17]. In 2007, we also carried out a
pilot study aimed at characterising the salivary proteo-
mic profile of 12 pSS patients in comparison to 12 sex-
and age-matched healthy individuals [12]. By using
quantitative two-dimensional electrophoresis (2DE) and
matrix-assisted laser desorption/ionisation time-of-flight
mass spectrometry (MALDI-TOF-MS), we identified 15
differently expressed proteins which apparently reflected
the various histopathological aspects of pSS, from acinar
loss, to lymphocytes infiltration, to local and systemic
flogosis. At the time, the pattern of identified proteins
was not preclinically validated.
The aim of the current study was, therefore, to analyse
by mass spectrometry techniques, coupled with Western
blot (WB) and enzyme-linked immunosorbent assay
(ELISA), the proteomic profile of pSS in an independent
larger cohort of patients not only in comparison to
healthy volunteers but also in comparison to pathologi-
cal controls. To this purpose, we included subjects with
non-SS sicca syndrome which may provide a natural
model of chronic dryness of the oral cavity not sus-
tained by an autoimmune response. Moreover, in order
to verify whether salivary proteomics might be utilised
to distinguish pSS from sSS the study was also extended
to patients affected by SS and concomitant RA (RA-sSS)
and SSc (SSc-sSS). The ultimate goal of this part of the
study was, in other words, to support the work hypoth-
esis that proteomic analysis of whole saliva could
represent a novel technique not only for the diagnosis
of disorders involving salivary glands but also systemic
autoimmune disorders even in the absence of any sali-
vary exocrinopathy.
Finally, we also explored the biological and pathoge-
netic function of the detected putative discriminatory
salivary proteomic biomarkers both in the local exocri-
nopathy and in the systemic inflammatory autoimmune
systemic processes of pSS by employing the Ingenuity
Pathway Analysis (IPA) Knowledge base.
Materials and methods
Study design
This diagnostic case-control study was subdivided into
three different steps. The first “exploratory” phase was
aimed at characterising the salivary proteomic profile of
a large group of pSS subjects in comparison to healthy
controls and pathological controls. The second “chal-
lenge” phase was aimed at preclinically validating by
WB and ELISA the ability of these candidate biomarkers
to differentiate pSS from healthy volunteers, subjects
with non-pSS sicca syndrome and patients with sSS.
ELISA results were also correlated to the minor salivary
gland focus score and to rheumatoid factor, anti-Ro/
SSA and anti-La/SSB. Finally, to investigate the biologi-
cal function of the significantly changing proteins, we
applied the Ingenuity Pathway Analysis (IPA) Knowl-
edge base (Ingenuity® System Inc., Redwood City, CA,
USA).This platform enabled us to visualize the potential
interactions between the identified biomarker signatures
in saliva and other molecules of interest, which may not
have been detected in this particular study, and to iden-
tify biological pathways underlying pSS disease process.
The study was approved by the local Ethics Committee
(Comitato per la sperimentazione clinica dei farmaci,
Azienda Ospedaliera Universitaria Pisana; reference
number 3062).
Patients’ inclusion and exclusion criteria
Patients with a diagnosis of pSS made according to the
International Classification Criteria for the disease
(AECG) [9], and healthy subjects with similar mean age,
and demographic characteristics were enrolled. The
study was also extended to pathological controls includ-
ing patients with non-SS sicca syndrome and patients
with RA-sSS and SSc-sSS. Similar to pSS, the diagnosis
of sSS was made according to the AECG classification
criteria [9] while the condition of non-SS sicca syn-
drome was defined as the presence of xerostomia and
xerophtalmia in patients with negative non-organ speci-
fic autoantibodies and negative minor salivary gland
biopsy (according to the Chisolm and Mason scoring
system).
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Detailed medical charts were available for all patients.
Variables analysed in the study included: sex, date of
diagnosis, date of salivary sample collection, disease
duration, presence of dry eyes and dry mouth, past or
present parotid enlargement and signs or symptoms
suggestive for any current or past extra-glandular invol-
vement (arthritis, lung involvement, skin vasculitis, per-
ipheral nervous involvement, kidney involvement).
Patients’ treatments were also recorded. Moreover, at
the time of the study entry, every patient had a com-
plete ophthalmological examination (including Schir-
mer’s test and Green Lissamine test), complete
laboratory tests, and an evaluation of the autoantibodies
profile (that is, antinuclear antibodies, extractable
nuclear antigen (ENA) antibodies, rheumatoid factor,
anticentromere auto-antibodies (ACA), Scl-70, anti-cyc-
lic citrullinated peptide (anti-CCP)). As far as laboratory
tests were related, a white blood cell count <4,000/mm3,
C3 <80 mg/dl, C4 <10 mg/dl, gamma-globulin >1.7 g/dl,
creatinine clearence <60 ml/minute, proteinuria >300
mg/day and urinary pH >6 were considered abnormal.
Antinuclear antibodies, ACA and Scl-70 antibodies were
assessed by indirect immunofluorescence, anti Ro/SSA,
La/SSB antibodies by controimmunoelectrophoresis,
rheumatoid factor by nephelometry and anti-CCP by
ELISA. A minor salivary gland biopsy was performed in
all cases. HIV-1, hepatitis B and hepatitis C infections
were also excluded in all of the participants. Written
informed consent was obtained from all patients and
healthy volunteers for their inclusion in the study.
Saliva collection and processing
Unstimulated whole saliva (WS) samples were collected
early in the morning in standard conditions, and the pre-
paration of the samples was performed as previously
described [12]. In order to minimize the degradation of
the proteins, the samples were processed immediately and
kept on ice during the process. Samples were immediately
centrifuged at 14,000 g for 30 minutes at 4°C to remove
debris and cells, and protein amounts of resulting superna-
tants were determined using the Bio-Rad protein assay.
Aliquots of the samples were stored at -80°C until analysis.
2DE analysis
The saliva specimens for each class were pooled and
each sample contributed to make the pool with an equal
amount of protein. We decided to carry out our study
on pooled samples due to the fact that the pool allowed
us to eliminate the intra-class variation even if the
response of single patients was lost. Salivary proteins
(150 µg) were solubilised in rehydration solution (7 M
urea, 2 M thiourea, 4% 3-((3-cholamidopropyl) dimethy-
lammonio)-1-propanesulfonate (CHAPS), 60 mM dithio-
threitol (DTT), 0.5% 3 to 10 ampholytes and 0.002% of
bromophenol blue). 2DE was performed using the
Immobiline-polyacrylamide system as previously
described [12]. Analytical gels were silver stained [18],
and preparative gels were stained using the Blue silver
protocol [19]. The 2-DE experiments were performed in
triplicate for each pool. No significant quantitative dif-
ferences among the replicates for each pool were
observed. The stained gels were scanned using an Epson
Expression 1680 Pro scanner (Seiko Epson Corporation,
Nagano, Japan ] and the images were analysed using
Image-Master 2D Platinum 6.01 (GE Health Care Eur-
ope, Uppsala, Sweden). After comparison of pSS with
respect to sSS and other sicca syndromes, proteins
whose expression showed over 1.5-fold statistical signifi-
cant spot quantity change were selected and identified.
In-gel digestion and mass spectrometry analysis
Spots of interest were cut out from the master gel and de-
stained by washing them with 50% acetonitrile in 50 mM
ammonium bicarbonate for 30 minutes. Gel pieces were
then dried for 30 minutes in a Hetovac vacuum centrifuge
(HETO, Allerod, Germany). Dried pieces of gel were sub-
jected to protein digestion by trypsin and peptide extrac-
tion. MS and MS/MS analysis of peptides from 2-DE gel
spots were performed with a 4800 Proteomics Analyzer
MALDI-TOF/TOF mass spectrometer (Applied Biosys-
tems, Framingham, MA, USA) according to the tuning
procedures suggested by the manufacturer. Peak lists were
generated with the Launch peak to MASCOT tools. Such
acquired MS and MS/MS data were compared to the data-
base using the MASCOT search engine [20]. In MASCOT,
the combined peptide mass fingerprint and MS/MS search
was performed on human entries present in Uni-
ProtSPTR database. Search settings allowed one missed
cleavage with the trypsin enzyme selected, one fixed modi-
fication (carboxymethylated cysteine) and one variable
modification (oxidation of methionine).
Scaffold (version Scaffold_2_03_01, Proteome Software
Inc., Portland, OR, USA) was used to validate MS/MS
based on peptide and protein identifications. Peptide
identifications were accepted if they could be established
at greater than 95.0% probability as specified by the Pep-
tide Prophet algorithm [21]. Protein identifications were
accepted if they could be established at greater than
95.0% probability and contained at least two identified
peptides. Protein probabilities were assigned by the Pro-
tein Prophet algorithm [22]. Proteins that contained
similar peptides and could not be differentiated based
on MS/MS analysis alone were grouped to satisfy the
principles of parsimony.
Principal component analysis of match set data
In order to identify patterns in the salivary protein pro-
files of the different patients’ groups, and to express the
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data in such a way as to highlight their similarities and
differences, a mathematical procedure, the principal
component analysis (PCA), was applied to the entire
data of the match sets, including healthy, pSS, non-SS
sicca syndrome and RA-sSS and SSc-sSS subjects. Nor-
malised spot data were imported from an Excel data-
sheet into the SIMCA-P+12 (Umetrics, Umeå, Sweden)
including the density data (% of volume) of about 700
spots/gel to observe the similarity among different
classes. To illustrate the arrangement of the clusters
produced by hierarchical clustering a tree diagram (den-
dogram) was produced displaying the results of the clus-
ter analysis.
Western blot (WB) analysis of the expression of b-2
microglobulin, a-enolase, immunoglobulin k light chain
(IGKC) and a-amylase fragmentation pattern
The WB was used to ensure the reliability of the 2DE
results. In particular, we investigated the expression of
b-2 microgloblulin, a-enolase, immunoglobulin k light
chain (IGKC) and the a-amylases. In order to character-
ise the fragmentation pattern of a-amylases, 2D blots
were performed using specific antibody direct versus the
full length of human recombinant protein in all the
groups. In the process of 1D WB, aliquots of samples
(pSS, RA-sSS, SSc-sSS, sicca) were mixed with a SDS
sample buffer (Laemmly solution) and heated at 100°C
for five minutes. The WB was carried out as exactly pre-
viously described [17]. Briefly, aliquots of proteins (25
μg), extracts from mix pooled WS samples of each class,
were loaded on 12% acrylamide gels and processed [23].
For the protein detection the following antibodies were
used: mouse monoclonal anti full length b-2 microglo-
blulin (sc-58903, Santa Cruz Biotechnology, Santa Cruz,
CA, USA), mouse monoclonal anti-a-enolase (sc-
100812, Santa Cruz Biotechnology), duck polyclonal anti
full length a-amylases (ab31147, Abcam, Cambridge,
UK) and rabbit polyclonal anti-IGKC (ab103827,
Abcam, UK) All the experiments were carried out in tri-
plicate. For each tested protein, the optical density of
specific immunoreactive bands was determined (Image J
software RSB, NIH, Betesda, Maryland, USA), and the
resulting mean values ± SD were compared.
For the detection of a-amylases, we chose a specific
antibody direct versus a full length of human recombinant
albumin, to detect the potential protein fragmentation.
Aliquots of 100 µg of proteins were separated by 2DE
using 3 to 10 linear strips 13 cm before Western blot ana-
lysis. The dilution was 1:500 and 1:10,000 for anti-a-amy-
lases primary antibody and anti-duck, respectively.
To assure a correct control of development conditions
a solution of standard proteins was loaded in each
experiment and the time and temperature of the process
were controlled.
ELISA
ELISA (E90260Hu, E961449Hu, Uscnk, Life Science Inc.
,Wuhan, P.R.China ) were used to determine the level
both of b-2 microglobulin and a-enolase in saliva sam-
ples from healthy (n = 21), pSS (n = 19), non-SS sicca
syndrome (n = 10) and sSS (n = 25) subjects. Whole sal-
iva samples were thawed, vortexed and centrifuged to
eventually remove mucins precipitation prior to assay-
ing. Saliva samples were diluted with 20 mM PBS buffer,
pH 7.2 at a final dilution of 1:100 and 1:5 for b-2 micro-
globulin and a-enolase, respectively. The assay was per-
formed according to the manufacturer’s instruction
manual. Samples were analysed in duplicate, and the
protein levels were determined according to the calibra-
tion curves established from standards (detection range
0.3 to 25 ng/ml).
Salivary a-amylase assay
For a-amylase a salivary a-amylase assay kit specifically
designed and validated for the kinetic measurement of
salivary a-amylase activity was used (catalog No 1-1902,
Salimetrics, LLC, State College, PA, USA). Saliva sam-
ples were diluted with a-amylase diluent provided at a
final dilution of 1:200. Aliquots of 8 μl of diluted sam-
ples were added to individual wells and the reaction was
started by the simultaneous addition of preheated (37°C)
a-amylase substrate solution. The enzymatic activity of
a-amylase on chromagenic substrate was determined
according to the manufacturer’s instruction manual at
405 nm. Results are expressed in U/mg of proteins. The
Salimetrics’ high and low salivary a-amylase controls
were run with each assay.
Statistical analysis
The optical density of the proteins was expressed as a
percentage of the volume (mean ± SD). The significance
of the differences (P-value <0.05) was calculated using
the ANOVA t-test and the Mann-Whitney test accord-
ing to data distribution. A multivariate analysis of
expression data of matched spots was conducted for all
classes and evaluated by principal component analysis
(PCA). The PC software SIMCA-P+12 (Umetrics, Umeå,
Sweden) was used in the PCA analysis.
Signalling pathways analysis
Functional pathway and network analyses were gener-
ated using the IPA software v7.1 (Ingenuity® System).
IPA identified the pathways from the IPA library of
canonical pathways that were most significant to the
data set. Proteins that met the expression ratio with a
cut-off ≥2.0, a P-value cut-off <0.05 for differential
expression and were associated with a canonical path-
way in the IPA Knowledge Base, were considered for
the analysis. Since one protein may have multiple
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functions, we selected the functions with P-value <0.015.
The network proteins associated with biological func-
tions and/or diseases in the IPA Knowledge Base were
considered for the analysis. These networks are scored
for degree of relevance with values >3 having a 99.9%
confidence level of not being generated by random
chance alone. The genetic networks that were created
describe functional relationships between gene products
based on known associations in the literature.
Results
Patients
One hundred and eighty subjects were included in the
study: 105 subjects were enrolled in the first “explora-
tory” phase and 75 in the second “challenge” phase.
That is, in the first part of the study, we included 40
women with a diagnosis of pSS made according to the
International Classification Criteria for the disease [9],
40 healthy age- and sex-matched women, 10 patients
with non-SS sicca syndrome, and in 15 patients with
sSS: 8 with RA-sSS, and 7 with SSc-sSS. Table 1 sum-
marises the demographic and clinico-serological features
of this training set of patients.
Patients affected by RA-sSS presented a median Dis-
ease Activity Score 28 (DAS28) of 3.8 ± 1.2. Seven of
them were anti-cyclic citrullinated peptide (CCP) anti-
bodies positive and six out of eight showed the presence
of bone erosions on X-ray. At the time of the enrolment
in the study, all the RA-sSS were on stable low-dose
prednisolone associated to biological or non biological
disease-modifying antirheumatic-drugs (DMARDs). In
more details, three patients were assuming leflunomide,
3 methotrexate in monotherapy and 2 methotrexate
plus an anti-TNF-a biological drug.
Patients with SSc-sSS presented a limited variant of
the disease with a positivity for ACA detected in five
cases out of seven. Only one patient had a past history
of interstitial lung disease. At the time of the enroll-
ment, all the patients showed only mild SSc related clin-
ical manifestations (that is, sclerodactily, Raynaud’s
Table 1 Primary, secondary SS and non-SS sicca patients’ demographic and clinical features
Data pSS (40) Sicca non-SS (10) RA-sSS (8) SSc-sSS (7)
Sex 40 F:0M 10 F:0M 8 F:0 M 7F:0M
Age (yrs) 52.4 ± 10.5 56.0 ± 10.7 60.8 ± 11.4 61.7 ± 8.1
Disease duration (yrs) 7 ± 6 3 ± 2 9 ± 7 7 ± 4
Oral symptoms 98% 80% 100% 86%
Ocular symptoms 97% 80% 100% 100%
Ocular tests (1) 100% 70% 100% 100%
Difficult in swallowing 19% 2% 12% 71%
Salivary gland enlargement 32% none 12% none
Minor salivary gland biopsy grading:
Chisolm and Mason grade 0, 1, 2 None 10/10 5/8 1/7
Chisolm and Mason grade 3 20/40 none 3/8 5/7
Chisolm and Mason grade 4 20/40 none none 1/7
Arthralgia 76% 1% 100% 57%
Arthritis 6% none 100% none
Fatigue 73% 30% 25% 29%
Raynaud’s phenomenon 43% 2% 12% 100%
Skin involvement 16% none 37% 14%
Dyspareunia 32% 2% none 14%
Interstitial lung disease None none 12% 14%
Peripheral nervous involvement 3% none 12% none
Kidney involvement 3% none none none
Leucopenia 30% none 12% 14%
Low C3 and/or C4 levels 33% 1% 12% 14%
Hypergammaglobulinemia 62% none 37% none
Antinuclear antibodies 94% 90% 62% 100%
Anti-Ro/SSA 70%/ none 25% 14%
Anti-La/SSB 36% none 12% none
Rheumatoid Factor 80% 2% 100% 29%
(1), Schirmer’s test and/or Lissamine Green; pSS, primary Sjögren’s syndrome; RA-sSS secondary Sjögren’s syndrome concomitant to rheumatoid arthritis; SS:
Sjögren’s syndrome; SSc: systemic sclerosis; SSc-sSS secondary Sjögren’s syndrome concomitant to systemic sclerosis; sSS: secondary Sjögren’s syndrome
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phenomenon, telangiectasias, eosophageal involvement,
arthralgias and digital ulcerations) requiring only low-
dose steroids, calcium channel blockers, prostacyclin
analogues, prokinetic agents and/or proton pump inhibi-
tors. None of the SSc-sSS patients had active lung inter-
stitial disease or pulmonary hypertension and none was
using immunosuppressive drugs when the salivary sam-
ples were collected.
In the second part of the study, the independent set
cohort included 75 unselected, consecutive subjects: 21
healthy volunteers (49.1 ± 9.8 years, mean age ± SD), 19
patients with a diagnosis of pSS (52.5 ± 14.3 years,
mean age ± SD), 10 patients with non-SS sicca syn-
drome (52.7 ± 17.9 years, mean age ± SD) and 25 sec-
ondary-SS (8 RA-sSS (59 ± 10.9 years, mean age ± SD)
and 17 SSc-sSS (51 ± 14.8 years, mean age ± SD).
Demographic and glandular manifestations of the valida-
tion cohort did not differ from the derivation cohort of
the subjects included in the first phase of the study.
Saliva collection and processing
Between 1 and 3 ml of saliva were obtained from each
subject. No differences were detected in the mean
volume of saliva collected from each group of patients.
In particular, we obtained a mean volume of 1.05 ± 0.77
ml of saliva from patients with pSS, 1.02 ± 0.78 ml from
patients with non-SS sicca symptoms and 1.06 ± 0.49
ml and 1.07 ± 0.34 from patients with RA-sSS and SSc-
sSS respectively.
Identification of differentially expressed salivary proteins
in pSS with respect to healthy, RA-sSS, SSc-sSS and non-
SS sicca syndrome
Typical 2DE gel images of exemplary gels of salivary
protein extracts from pooled samples of healthy volun-
teers, pSS patients, RA-sSS, SSc-sSS and non-SS sicca
syndrome subjects are shown in Figures 1 and 2. By
computational gel image comparison, a total of 28, 6, 7
and 12 protein spots were found to be differentially
expressed in healthy volunteers, non-SS sicca syndrome,
SSc-sSS and RA-sSS salivary profiles, with respect to
pSS samples. For “representative” salivary proteins, the
identification was obtained by direct comparison with
images of previous studies. For unknown proteins, we
proceeded with MS/MS analysis. Of the 15 cut spots,
80% were identified by MS/MS spectrometry, yielding 9
different protein identifications. A list of identified pro-
teins, MW, isoelectric point (pI) score and coverage
values of MS/MS is shown in Table 2.
Table 3 summarises the most significant differences
among pSS patients, healthy volunteers and non-SS
sicca syndrome in the expression of both “representa-
tive” and newly identified salivary proteins. In addition,
the fold changes of the expression of previously and
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Figure 1 Representative 2D map of primary Sjögren’s syndrome (pSS) (A) and healthy subject (B). A total of 150 µg of whole saliva
proteins was separated by 2D using 18 cm pH 3 to 10 L strip (IPG) and 12.5% SDS-PAGE. Proteins were detected by silver staining. The map
was analysed by Image master 2D platinum software. Spot numbers indicate all the proteins identified by MS/MS and refer to the number
reported in Tables 2-4.
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newly identified proteins in RA-sSS and SSc-sSS subjects
with respect to pSS, and the relative P-values, are shown
in Table 4. The proteins found to be differentially
expressed are also circled in the representative gels (Fig-
ures 1 and 2).
As described in Table 3, 12 proteins were differently
expressed in pSS with respect to healthy volunteers.
Among them, six proteins showed a >1.5-fold of
increase in pSS (that is, calgranulin B [UniProtKB:
P06702], b-2 microglobulin [UniProtKB:P61769], epider-
mal fatty acid binding protein (E-FABP) [UniProtKB:
Q01469], psoriasin [UniProtKB:P31151], IGKC protein
([UniProtKB:Q6GMW1] and a-enolase (47 KDa) [Uni-
ProtKB:P06733]) and six were characterised by a >1.5
Figure 2 Representative 2D map of secondary Sjögren’s syndrome and other sicca syndromes. (A) non-SS sicca syndrome, (B) secondary
Sjögren’s syndrome concomitant to rheumatoid arthritis RA-sSS and (C) secondary Sjögren’s syndrome concomitant to systemic sclerosis SSc-sSS
whole saliva proteins. A total of 150 µg of proteins was separated by 2D using 18 cm pH 3 to 10 L strip (IPG) and 12.5% SDS-PAGE. Proteins
were detected by silver staining. The map was analysed by Image master 2D platinum software. Spot numbers indicate all the proteins identified
by MS/MS and refer to the number reported in Tables 2-4.
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fold decrease (that is, a-amylases precursor [UniProtKB:
P04745], carbonic anhydrase VI [UniProtKB:Q5FC00],
cystatin SN precursor [UniProtKB:P01037], prolactin-
inducible protein precursor (PIP) [UniProtKB:P12273],
short palate, lung and nasal epithelium clone 2 (SPLUNC-
2) [UniProtKB:Q96DR5], glyceraldehydes-3-phosphate
dehydrogenase (G3PDH) [UniProtKB:P04406]). When pSS
patients were compared to patients affected by non-SS
sicca syndrome, a-amylases precursor, carbonic anhydrase
VI, G3PDH and SPLUNC-2 were still significantly
decreased in the former group, while, on the contrary E-
FABP, b-2 microglobulin and IGKC protein showed a per-
sistent, significant increase. Three more proteins were dif-
ferently expressed in pSS with respect to sSS (Table 4):
lipocalin [UniProtKB:P31025] and rheumatoid factor D5
light chain [UniProtKB:A0N5G5] which were respectively
increased and decreased in RA-sSS, and Cystatin C [Uni-
ProtKB:P01034], which was significantly reduced in SSc-
sSS. No further differences were documented between pSS
and sSS with the exception of b-2 microglobulin, which
was increased in pSS in comparison to both RA-sSS and
SSc-sSS, IGKC protein which was significantly decreased
in RA-sSS and G3PDH, which was decreased in SSc-sSS.
Finally, we observed that single spots of the same proteins
were characterised by a different optical density in pSS-
patients and controls. From this point of view, we found
that the spots n° 2543 (47 KDa a-enolase), n° 3034 and
3017 (calgranulin B) were significantly increased in RA-
Table 2 MS/MS data of differential protein spots from pSS, non-SS sicca syndrome and sSS syndromes
Spot
No
Accession
No a
Protein name Gene
name
Theoretical
Mr b
Theoretical
pI b
Matched
peptides c
Coverage
(%)
Peptides
identified d
2261 P04745 a-amylase 1 AMY1A 58 6.47 16 43 RSGNEDEFRN
2842 Q6GMW1 IGKC protein IGKC 26 6.9 8 33 KSFNRGE
2439
2543
P06733 a-enolase ENO1 47 7.01 8 25 RNFRNPLAK
2640
2642
P04406 G3PDH GAPDH 36 8.57 3 9 KAGAHLQGGAKRV
3017
3034
P06702 Protein S100-A9 S100A9 13 5.71 4 43 RLTWASHEKM
2996 P01034 Cystatin-C CST3 16 9.00 6 49 KASNDMYHSRA
3018 P31151 Protein S100-A7 S100A7 11 6.27 3 26 RSIIGMIDMFHKY
2832 A0N5G5 Rheumatoid factor D5 light chain
(Fragment)
V<kappa>3 13 9.15 2 23 RLLIYDASNRA
2954 P31025 Lipocalin-1 LCN1 19 5.39 3 27 RGLSTESILIPRQ
a) Accession number was derived from the ExPASy database. b) Theoretical molecular weight (kDa) and pI from the ExPASy database. c) The number of peaks
which match to the trypsin peptides. d) Each spot corresponding to one certain protein had at least one of the shown peptides identified.
G3PDH, glyceraldehydes-3-phosphate dehydrogenase; IGKC: immunoglobulin k light chain; pSS, primary Sjögren’s syndrome; SS: Sjögren’s syndrome; SSc-sSS
secondary Sjögren’s syndrome concomitant to systemic sclerosis; sSS: secondary Sjögren’s syndrome.
Table 3 Differential protein spots from pSS, healthy volunteers and non-SS sicca syndrome patients (P <0
Spot
No
Accession
No
Protein name Gene
name
Mean ±
SD
(pSS)
Mean ±
SD
(healthy)
Mean ± SD
(sicca non-
SS)
Fold of
variation
pSS vs healthy
Fold of variation
pSS vs sicca non-
SS
2261 P04745 a-amylases precursor AMY1A 2.58 ± 0.44 4.77 ± 0.39 4.24 ± 0.67 -1.8** -1.6**
2572 Q5FC00 Carbonic anhydrase VI CA6 0.65 ± 0.11 1.50 ± 0.47 1.07 ± 0.26 -2.3* -1.6*
2642 P04406 G3PDH GAPDH 0.07 ± 0.03 0.31 ± 0.03 0.23 ± 0.85 -4.4*** -3.2*
2543 P06733 a-enolase ENO1 0.08 ± 0.02 0.04 ± 0.01 0.05 ± 0.03 +2** +1.6
2842 Q6GMW1 IGKC IGKC 1.33 ± 0.49 0.17 ± 0.30 0.54 ± 0.42 +7.8* +2.5
3018 P31151 Protein S100-A7 (Psoriasin) S100A7 0.47 ± 0.21 0.09 ± 0.04 0.32 ± 0.15 +5.2* +1.5
3000 P06702 Protein S100-A9 (Calgranulin
B)
S100A9 2.98 ± 0.10 2.00 ± 0.42 2.75 ± 0.54 +1.5* ns
2986 P01037 Cystatin SN precursor CST1 0.91 ± 0.36 2.37 ± 0.01 0.84 ± 0.44 -2.6** ns
2938 P12273 PIP PIP 0.05 ± 0.08 0.33 ± 0.01 0.09 ± 0.17 -6.6** -1.8
2655 Q96DR5 SPLUNC-2 SPLUNC2 0.04 ± 0.07 0.40 ± 0.17 0.40 ± 0.18 -10* -10*
3003 Q01469 E-FABP FABP5 0.17 ± 0.07 0.02 ± 0.03 0.06 ± 0.05 +8.5* +2.8*
3036 P61769 b-2 microglobulin B2M 0.39 ± 0.04 0.17 ± 0.04 0.23 ± 0.05 +2.3** +1.7
NB, values that are significantly different from pSS (*P <0.05, **P <0.01, ***P <0.001) as determined by statistical analysis. E-FABP, epidermal fatty acid binding
protein; G3PDH, glyceraldehydes-3-phosphate dehydrogenase; IGKC, immunoglobulin k light chain; PIP, prolactin-inducible protein precursor; pSS, primary
Sjögren’s syndrome; SPLUNC-2, lung and nasal epithelium clone 2; SS, Sjögren’s syndrome
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sSS while the spot n° 2439 (59KDa a-enolase) was signifi-
cantly decreased in RA-sSS in comparison to pSS.
Principal component analysis (PCA) of match set data
Figure 3 shows the dendogram obtained after the PCA
application to the entire data of the match sets,
including healthy, pSS, non-SS sicca syndrome and RA-
sSS and SSc-sSS subjects. The vertical axis indicates the
loss in within-cluster similarity, that is, the variance
increase when the clusters are merged. A close relation-
ship was observed between pSS and RA-sSS (Group 1),
while on the other hand non-SS sicca syndrome and
Table 4 Differential protein spots in pSS, RA-sSS and SSc-sSS (P <0
Spot No Accession No Protein name Gene name Mean ± SD
(pSS)
Mean ± SD
(RA- sSS)
Mean ± SD
(SSc-sSS)
Fold of variation
pSS vs RA- sSS
Fold of variation
pSS vs SSc-sSS
3017 P06702 (Protein S100-A9)
Calgranulin B
S100A9 0.15 ± 0.07 0.37 ± 0.07 - -2.46* -
3034 P06702 (Protein S100-A9)
Calgranulin B
S100A9 0.20 ± 0.09 0.56 ± 0.17 - -2.8* -
2439 P06733 a-enolase ENO1 0.13 ± 0.02 0.05 ± 0.02 - +2.6** -
2543 P06733 a-enolase ENO1 0.08 ± 0.02 0.19 ± 0.03 - -2.4** -
2842 Q6GMW1 IGKC IGKC 1.33 ± 0.49 0.05 ± 0.09 - +26* -
2832 A0N5G5 Rheumatoid factor D5
light chain
V<KAPPA>3 1.97 ± 0.11 0.29 ± 0.26 - +6.8*** -
2954 P31025 Lipocalin LCN1 0.06 ± 0.05 0.37 ± 0.07 - -6.2** -
3036 P61769 b-2 microglobulin B2M 0.39 ± 0.04 0.25 ± 0.04 0.25 ± 0.03 +1.6* +1.6*
2642 P04406 G3PDH G3PDH 0.07 ± 0.03 - 0.19 ± 0.10 - -2.7*
2996 P01034 Cystatin-C CST3 0.21 ± 0.08 - 0.05 ± 0.04 - -4.2*
NB, values that are significantly different from pSS (*P <0.05, **P <0.01, ***P <0.001) as determined by statistical analysis.
G3PDH, glyceraldehydes-3-phosphate dehydrogenase; IGKC, immunoglobulin k light chain; pSS, primary Sjögren’s syndrome; RA-sSS, secondary Sjögren’s
syndrome concomitant to rheumatoid arthritis; SSc-sSS, secondary Sjögren’s syndrome concomitant to systemic sclerosis
he
ig
ht
No Group (x= 0.68; y =823); Group 1 (x =0.32; y = 146); Group 2 (x= 0.48; y =103); Group 3 (x= 0.84; y= 76)
Group 1 Group 2
Group 3
No Group
Hierarchical Cluster Analysis
Figure 3 Dendogram obtained after PCA. The dendrogram is a graphical representation of the results of hierarchical cluster analysis. This is a
tree-like plot where each step of hierarchical clustering is represented as a fusion of two branches of the tree into a single one. The branches
represent clusters obtained on each step of hierarchical clustering. A close relationship was observed between primary Sjögren’s syndrome (pSS)
and patients with secondary Sjögren’s syndrome (sSS) concomitant to rheumatoid arthritis (RA-sSS) classes while sicca syndrome and healthy
volunteers appeared to be more similar. The protein profile of patients with secondary Sjögren’s syndrome (sSS) concomitant to systemic
sclerosis (SSc-sSS) was placed at an intermediate level between the previously mentioned clusters.
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healthy volunteers appeared to be more similar to each
other (Group 3). The protein profile of SSc-sSS patients
was placed at an intermediate level between the pre-
viously mentioned clusters, and created a different
group together with non-SS sicca syndrome and healthy
volunteers (Group 2).
Validation of b-2 microglobulin, IGKC and a-enolase
protein by WB analysis and ELISA
A representative immunoblot of b-2 microgloblulin, a-
enolase and IGKC and the resulting mean optical den-
sity values ± SD is represented in Figure 4 (Figure 4, bar
graphs). As shown in the figure, WB analysis confirmed
a significant increase of b-2 microglobulin (P-value =
0.02) and IGKC protein (P = 0.01) in pSS with respect
to healthy volunteers while documented only a trend in
favour of the increased of a-enolase (47 KDa) (pSS vs
healthy volunteers, P = 0.08). In fact, b-2 microglobulin
(P <0.001) and a-enolase (47KDa) (P = 0.002) were both
found statistically significant in pSS vs healthy volun-
teers at the ELISA test (Table 5). WB also confirmed a
significant increase of IGKC protein in pSS with respect
to RA-sSS (P = 0.01, WB).
As far as the expression of b-2 microglobulin among
pathological controls was related, discordant data were
observed both at the WB and the ELISA tests. Overall,
taking into account the 2DE data and the of WB and
ELISA results, we hypothesised a trend in favour of
increased b-2 microglobulin levels in pSS in comparison
to both non-SS sicca syndrome (P = 0.11, WB; P =
0.087, ELISA test), RA-sSS (P = 0.02, WB; P = 0.51,
ELISA test) and SSc-sSS (P = 0.53, WB; P = 0.05, ELISA
test). Intriguingly, we also found a significant association
between b-2 microglobulin (ELISA test) and anti-Ro/
SSA antibodies (P = 0.008). As far as a-enolase protein
was concerned, the resulting immunoreactive pattern
confirmed the presence of two specific bands with a dif-
ferent level of intensity. The major immunoreaction was
protein pSS healthy sicca RA-sSS
SSc-
sSS
MW
Į-enolase
ȕ-2-microglobulin
IGKC protein
59 KDa
47 KDa
7 KDa
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Alpha-enolase 59 Alpha-enolase 47 ß-2-microglobulin IGKC protein
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*
Figure 4 Validation of a-enolase, b-2 microgloblulin and immunoglobulin k light chain (IGKC). (A) Conventional SDS gels were run with
protein extracts from mix pooled WS samples of primary Sjögren’s syndrome (pSS), non-SS sicca syndrome, RA-sSS and SSc-sSS syndromes
patients using 12% resolving capacity. Twenty-five micrograms of total proteins were loaded into each lane for each sample. Proteins were
transferred onto nitrocellulose membranes and incubated with specific antibodies (dilution 1:200 for anti-a-enolase and anti-b-2 microgloblulin;
dilution 1:10,000 for anti-IGKC) against the target proteins. (B) Densitometry of the blots was performed and the bar graph shows the mean ±
SD of the optical density values of three independent experiments. Values that are significantly different from pSS (*P <0.05, **P <0.01, ***P
<0.001) value as determined by statistical analysis.
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with a protein of 59 kDa, while the other was at 47 kDa.
These results were in agreement with those obtained by
2DE/MS/MS analysis which documented two different
spots (n° 2439 and n° 2543), both identified as a-eno-
lase. In particular, the 47 kDa band (spot n° 2543) was
expressed at the highest levels in RA-sSS (pSS vs RA-
sSS P-value = 0.0013, WB) while the 59 kDa band (spot
n° 2439) was significantly reduced (pSS vs RA-sSS P-
value = 0.03, WB). At the ELISA test, a-enolase resulted
as not differently expressed in RA-sSS and in pSS (P =
0.204); however, we found that a-enolase was still signif-
icantly increased in RA-sSS with respect to healthy
volunteers (P = 0.001) and that a-enolase was signifi-
cantly associated to rheumatoid factor (P = 0.03). No
significant associations were found between ELISA test
results and minor salivary gland biopsy focus score.
The immune reactive pattern of a-amylases
fragmentation
Regarding a-amylases fragmentation, in addition to the
main spot of the a-amylases precursor, the immunor-
eactive pattern documented in pSS and sSS, a number
of additional spots identified as a-amylases which were
distributed in a large pI range with a different level of
intensity suggesting a typical profile of protein fragmen-
tation (Figure 5). These observations and the fact that
enzymatic activity assay did not document any differ-
ence in the levels of the a-amylases among pSS patients
and healthy or pathological controls (Table 5) allowed
us to make the hypothesis that a-amylases fragmenta-
tion might be considered as the principal mechanism
responsible for the decrease of the main spot of a-amy-
lases precursor in pSS and sSS with respect to non-SS
sicca syndrome and healthy volunteers.
Network construction for biological processes
Three networks were generated by the Ingenuity soft-
ware. The one with the highest score (score value 20) is
shown in Figure 6. This network shows 35 proteins that
work together for Cellular Movement, Haematological
System Development and Function, Haematopoiesis,
and 9 of these 35 proteins were found in our salivary
proteome. Genes or gene products are represented as
nodes, and the biological relationship between two
nodes is represented as an edge (line). Figure 6 shows
the direct or indirect relationships exhibited by the pro-
teins with each other within the network by using solid
and dashed lines respectively. The figure clearly shows
that TNF, nuclear factor-kappa B (NF-kB) and IgG are
key nodes within the network. These key gene nodes are
connected directly and indirectly to many of the puta-
tive salivary protein biomarkers identified in pSS. The
identified proteins included: E-FABP, b-2 microglobulin,
calgranulin B (protein S100-A9), psoriasin (protein
S100-A7), and a-enolase. The IPA demonstrated that
the major involved biological functions resulted in the
following categories: inflammatory response pathways,
lipid metabolism processes, molecular transport,
immune cell trafficking, cancer and haematological dis-
ease categories.
Discussion
The overall results of this study allowed us to verify and
pre-clinically validate in a large cohort of patients a
number of potential discriminatory biomarkers in the
whole saliva of pSS, in comparison to both healthy
volunteers and pathological controls. In this study we
found that the pSS salivary profile was characterised by
a decrease in many secretory proteins (that is, a-amy-
lases precursor, carbonic anhydrase VI, PIP, SPLUNC-2,
G3PDH, and cystatins), an increase of proteins related
to the autoimmune response (that is, b-2 microglobulin,
IGKC protein, and rheumatoid factor D5 light chain)
and an increase of proteins related to systemic and local
inflammation (a-enolase, lipocalin and S100-A7 and A9
proteins). On the other hand, as expected, subjects with
RA-sSS or SSc-sSS shared a number of salivary biomar-
kers, whereas subjects with sicca complaints but without
Table 5 Mean values of salivary marker proteins
b-2 microglobulin
mean ± SD (μg/ml)
a-enolase
mean ± SD (ng/ml)
a-amylase
mean ± SD (U/mg of proteins)
pSS 1.7 ± 0.5 82.4 ± 34.1 35.7 ± 17.5
healthy 0.8 ± 0.3 37.0 ± 27.3 34.5 ± 15.5
P-value vs pSS <0.001 0.002 0.893
sicca non-SS 1.3 ± 0.7 74.2 ± 33.4 40.0 ± 18.7
P-value vs pSS 0.08 0.191 0.538
RA- sSS 1.5 ± 0.8 103.0 ± 15.4 35.3 ± 19.9
P-value vs pSS 0.514 0.204 0.96
SSc-sSS 1.5 ± 0.6 78.2 ± 31.6 38.0 ± 22.3
P-value vs pSS 0.05 0.392 0.718
pSS, primary Sjögren’s syndrome; RA-sSS, secondary Sjögren’s syndrome concomitant to rheumatoid arthritis; SSc, systemic sclerosis; SSc-sSS, secondary Sjögren’s
syndrome (sSS) concomitant to systemic sclerosis; sSS, secondary Sjögren’s syndrome.
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SS were characterised by a proteomic profile much closer
to that of healthy subjects with the exception of an
increase of proteins related to inflammation (that is, S100
proteins) and a decrease of secretory proteins, such as PIP
and SPLUNC-2. In fact, the latter was still significantly
increased in patients with non-SS sicca with respect to
pSS patients while PIP showed a one-fold variation when
compared to pSS. The similarities and the differences
between the groups were clearly displayed in the dendo-
gram representation. The dendogram showed, in particu-
lar, that pSS and RA-sSS were so close in value that
together they made a cluster easily distinguishable from
the other groups. Subjects with SSc-sSS created a second,
different cluster which was in between the others, showing
not only a reduction of many acinary proteins and an
increase of proteins related to lymphocyte activation, but
also an increased expression of G3PDH which was closer
to the profiles of non-SS sicca syndrome patients and
healthy volunteers. In turn, healthy volunteers and patients
with non-SS sicca syndrome were apparently very similar
and represented a third cluster.
These results confirmed our previous preliminary data
[12] and pre-existing literature [13-17]. However, in this
study, the expression of salivary biomarkers was also
verified in an independent cohort of healthy volunteers
and pathological controls, distinct from the derivation
cohort, by using additional antibody detection tests (WB
and ELISA). This allowed us to conclude that a panel of
candidate biomarkers rather than a single specific pro-
tein may apparently be able to better distinguish pSS
from healthy volunteers and other pathological
disorders.
In the present study, we first described 15 proteins
which could represent candidate biomarkers to be
included in a potential diagnostic panel for pSS. Some
of them appeared to be significantly increased (that is,
psoriasin) or decreased (that is, cystatin SN, PIP) only in
comparison with healthy volunteers and, therefore, their
diagnostic role for pSS remains controversial. On the
contrary, out of the identified 15 proteins, a-amylases
precursor, b-2 microglobulin, G3PDH, IGKC protein, E-
FABP, carbonic anhydrase VI and SPLUNC-2 showed
the most significant differences in the expression in
comparison both to healthy volunteers and non-SS sicca
syndrome and, therefore, appeared to be the most sig-
nificant discriminatory biomarkers for SS.
pSS 
SSc-sSS 
healthy 
sicca RA-sSS 
Figure 5 Immunoblot of the a-amylase in pSS, non-SS sicca syndrome, RA-sSS and SSc-sSS syndromes. The pattern of expression of a-
amylases protein was investigated in different classes of patients by 2DE and subsequently by WB with specific antibody direct versus full length
of human recombinant protein. Aliquots of 100 µg of proteins extracts from mix pooled WS samples of each class were separated by 2DE using
3 to 10 linear strips 13 cm before Western blot analysis. The dilution was 1:500 and 1:10,000 for anti-a-amylase primary antibody and anti-duck,
respectively.
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A role for these proteins of potential biomarkers for
pSS and sSS has been already hypothesised by previous
proteomic studies. In particular, Ryu et al. [13] demon-
strated a significant increase of b-2 microglobulin and
IGKC protein and a reduction of a-amylases precursor
and carbonic anhydrase VI in the stimulated parotid sal-
iva obtained from 41 primary SS patients. A significant
reduction of a-amylases in pSS was also reported by
Peluso and co-workers [14]. In the present work, we
confirmed the significant decrease of the main spot of
a-amylases precursor in pSS and sSS with respect to
healthy volunteers and non-SS sicca syndrome. We also
found that the pSS salivary profile was characterised by
a peculiar abundance of a-amylases precursor frag-
ments. We concluded that to a certain extent, the
decrease of this acinar protein might be explained by
pSS fragmentation processes which have been previously
reported as related to an unbalanced expression of pro-
teases and proteases inhibitors [12]. We also documen-
ted an increase of IGKC protein, rheumatoid factor D5
light chain and b-2 microglobulin. As far as b-2 micro-
globulin is related, Hu S and coworkers [15,17] identi-
fied and preclinically validated b-2 microglobulin,
cathepsin D, and a-enolase as potential biomarkers for
pSS. In the current study we were unable to identify
cathepsin D. However, in line with the studies by Hu S
Threeshold(p<0.015)
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& Interaction
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Cellular Movement
Hematological System 
Development and Function
Hematopoiesis
Immune Cell Trafficking
BA
Figure 6 Network analysis of differentially expressed proteins using the IPA software. Proteins of WS that were found to be significantly
different among pSS, non-SS sicca syndrome, RA-sSS and SSc-sSS syndromes were analysed by using IPA. (A) This network shows 35 proteins
that work together for Cellular Movement, Haematological System Development and Function, Haematopoiesis. Ten of these 35 proteins were
found in our salivary proteome. Protein-to-protein direct (solid lines) or indirect (dashed lines) interactions/regulations, based on information
published in the literature are shown in the figure. In the panel B, the top 17 functions of the proteins identified in the network are shown.
Proteins were matched to 72 functions with significance above 1.83 (P <0.015). The top 17 functions involving the 35 proteins are shown here
with the number of associated proteins that were identified for each function. ACTB, actin beta; ALB, albumin, B2M, beta2microglobulin;
CLEC11A, C-type lectin domain family 11 member A; COPS5, COP9 signalosome complex subunit 5; CTSC, cathepsin C; CXCL16, C-X-C motif
chemokine 16; CXCL3, C-X-C motif chemokine 3; DLEU1, Leukemia-associated protein 1; ENO1, Alpha-enolase; FABP5, fatty acid-binding protein,
epidermal; FCGR1C, putative high affinity immunoglobulin gamma Fc receptor IC; FCGRT, IgG receptor FcRn large subunit p51; FST, follistatin;
GSTP1, glutathione S-transferase P; IFN-b1, interferon beta; IgG, immunoglobulin G; IL1F8, interleukin 1 family, member 8; IL8, interleukin 8; JNK,
c-Jun N-terminal kinase; LNB, Lymphotoxin beta; MYC, v-myc myelocytomatosis viral oncogene homolog (avian); NFkB (complex), nuclear factor
NF-kappa-B; PPP1R15A, protein phosphatase 1 regulatory subunit 15A; PTAFR, platelet-activating factor receptor; RND3, rho-related GTP-binding
protein RhoE; S100A7, psoriasin 1; S100 A8, protein S100-A8; S100A9, protein S100-A9; SERPINB1, leukocyte elastase inhibitor; TAPBP, tapasin-
related protein; TBP, TATA box binding protein; TNF, tumor necrosis factor; TNFAIP3, tumor necrosis factor, alpha-induced protein 3; TNFSF15,
tumor necrosis factor ligand superfamily member
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et al. [15,17] we found that b-2 microglobulin was sig-
nificantly increased in pSS. WB and ELISA tests con-
firmed a trend in the expression of the protein with the
highest levels in pSS and the lowest levels in healthy
volunteers and a significant association between b-2
microglobulin and antiRo/SSA positivity was also found.
The increased expression of this protein in pSS whole
saliva might thus reflect both the systemic B-cells activa-
tion and the increased intra-glandular immunoglobulin
synthesis, which are peculiar aspect of the disease
[23-25].
Finally, we also documented an increase in the salivary
expression of a-enolase in pSS in comparison to healthy
controls. In addition, we also found that a-enolase (47
KDa) was significantly higher in patients with RA-sSS
with respect to pSS and significantly associated to the
positivity for rheumatoid factor (P = 0.03). Similar
trends were also reported for lipocalin and for many
spots of calgranulin B (S100-A9) which showed the
highest levels in RA-sSS patients. Intriguingly, since
increased levels of all these proteins have been already
reported in biological fluids of patients with RA without
sSS [26,27], we speculated that proteomic analysis of
whole saliva could represent a novel technique not only
for the diagnosis of disorders involving salivary glands
but also for systemic autoimmune disorders even in the
absence of any salivary exocrinopathy. In line with this
work hypothesis, we also found, in this study, that the
salivary profile of patients with SSc-sSS, was charac-
terised by a significant increase of G3PDH, which has
been already described in whole saliva of patients with
SSc without sSS [28].
Moreover, in addition to the mentioned potential
diagnostic applications, our results support the hypoth-
esis that the entire proteome of saliva might mirror the
disease process and provide useful insights into the
pathogenesis of the lesions helping to monitor the evo-
lution of the disease process over time. The potential
impact of the proteomic approach in the pathogenetic
research of autoimmune diseases might be emphasized
if we employ a novel statistical platform, the IPA
Knowledge base, to the analysis of biomarkers signatures
in pSS. We found that many of the involved candidate
biomarkers could be associated in a network which was
able to mirror many of the several pathways involved in
the pathogenesis of pSS. In this study, the biological
functions that received the highest score of association
with the protein panels were represented by cellular
trafficking and movement, cell-to-cell interaction,
inflammatory response, cell death, haematological sys-
tem function and haematological cancers. Interestingly,
all these biological processes are known to take part in
many of the pathophysiological steps of the disease from
the gland infectious and/or immune-mediated attack to
lymphoproliferation [29,30]. Looking at the nodes of the
network, which were represented by interferon-b (IFN-
b), the interleukin-8 (IL-8), the tumour necrosis factor-
a (TNF-a) and the NF-kB many potential speculations
might arise. For example, an enhanced activity of the
type-I IFN system (and to a lesser extent of type-II IFN
system) has been associated to the early stages of pSS
pathogenesis, and can be considered the link between
the disease onset and an hypothetical environmental
trigger (that is, infectious agent) in genetically predis-
posed subjects [29,30]. Moreover, an increased expres-
sion of IFN-regulated genes has been described in pSS
salivary glands [15] and correlated with the production
of anti-Ro/SSA and anti-La/SSB auto-antibodies and
with the up-regulation of numerous INF-induced che-
mokines (that is, CXCL10, CXCL13) [31-35]. Finally, IL-
8 is involved mainly in cellular trafficking and defence,
while TNF-a and NF-kB are important inducers of
inflammatory response and apoptosis, and may amplify
the autoimmune deregulation contributing to the apop-
totic death of epithelial cells, to ductal hyperplasia and
glandular fibrosis, all recognised hallmarks of pSS
[30,34].
Conclusions
In conclusion, this study demonstrated that novel, non-
invasively-collected salivary proteomic biomarkers might
be helpful for an early and accurate characterisation of
pSS and sSS. We focused the attention on a panel of
seven proteins which were at the same time differently
expressed in pSS, non-SS sicca syndrome and healthy
volunteers. In addition, we found that some of the sSS
identified biomarkers apparently reflected not only the
SS component but also the concomitant systemic auto-
immune disorders shedding new light on the potential
diagnostic role of saliva in autoimmune diseases irre-
spectively from salivary glands involvement. Of course,
this study has some limitations: 2DE gels were obtained
by pooling the salivary samples of each group, WB and
ELISA tests were performed only for a-enolase, b-2
microglobulin, and a-amylases. However, this study
soundly confirmed that saliva might have a great poten-
tial as a novel biofluid for the diagnosis of systemic
autoimmune disorders with definite advantages in terms
of non-invasiveness and reproducibility. Finally, in this
study salivary proteomics also appeared to be useful in
exploring the pathogenetic pathways of different sys-
temic disorders. It would be advisable, as a potential
development of this work, to set up, in the near future,
different strategies to measure easily the single compo-
nents of the identified proteomic salivary panel in single
patients in order to develop a multivariate prediction
model able to improve a screening diagnostic process
for pSS in clinical practice. This will allow the clinician
Baldini et al. Arthritis Research & Therapy 2011, 13:R194
http://arthritis-research.com/content/13/6/R194
Page 14 of 16
to take full advantage of the many potentialities of sali-
vary fluid as an ideal milieu for the diagnosis of pSS and
other systemic diseases and for the identification of the
pathogenetic processes underlying glandular and sys-
temic disorders.
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